Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Masayoshi Harigai, Naoki Ishiguro, Shigeko Inokuma, Tsuneyo Mimori, Junnosuke Ryu, Syuji Takei, Tsutomu Takeuchi, Yoshiya Tanaka, Yoshinari Takasaki, Hisashi Yamanaka, Yuri Yoshizawa, Ichino Chinen, Toru Nakao & Takao Koike. (2019) Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. Modern Rheumatology 29:5, pages 747-755.
Read now
Read now
Kosaku Murakami, Masahiro Sekiguchi, Shintaro Hirata, Takao Fujii, Kiyoshi Matsui, Satoshi Morita, Koichiro Ohmura, Yutaka Kawahito, Norihiro Nishimoto, Tsuneyo Mimori & Hajime Sano. (2019) Predictive factors for structural remission using abatacept: Results from the ABROAD study. Modern Rheumatology 29:3, pages 406-412.
Read now
Read now
Takeshi Mochizuki, Katsunori Ikari, Koichiro Yano, Motoaki Sato & Ken Okazaki. (2019) Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. Modern Rheumatology 29:3, pages 413-417.
Read now
Read now
Noriyoshi Ogawa, Hiroyuki Ohashi, Yasuhiro Ota, Kaori Kobori, Motohiro Suzuki, Seiji Tsuboi, Masakatsu Hayakawa, Yoshinori Goto, Taro Karahashi, Osamu Kimoto, Toshiaki Miyamoto, Shogo Furukawa, Kumiko Shimoyama, Daisuke Suzuki & Yuichiro Maekawa. (2019) Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis. Immunological Medicine 42:1, pages 29-38.
Read now
Read now
Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ryo Hiroshima, Kosei Kawakami, Naoko Koenuma, Mina Ishibashi & Shigeki Momohara. (2018) The efficacy of abatacept focusing on anti-CCP antibody in Japanese patients with rheumatoid arthritis for 104 weeks. Modern Rheumatology 28:3, pages 575-577.
Read now
Read now
Ayaka Yoshikawa, Shuzo Yoshida, Yuko Kimura, Nao Tokai, Yohei Fujiki, Takuya Kotani, Yoko Matsumura, Tohru Takeuchi & Shigeki Makino. (2018) Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Modern Rheumatology 28:2, pages 227-234.
Read now
Read now
Articles from other publishers (6)
Kenji Takami & Shigeyoshi Tsuji. (2023) Real-world retention rates of biologics in patients with rheumatoid arthritis. Scientific Reports 13:1.
Crossref
Crossref
Moiz Ehtesham, Anupama Tiwari, Rose Sneha George & Ruben A. Peredo. 2022. Idiopathic Pulmonary Fibrosis. Idiopathic Pulmonary Fibrosis.
Sei Muraoka, Zento Yamada, Mai Kawazoe, Wataru Hirose, Hajime Kono, Shinsuke Yasuda, Yukiko Komano, Hiroshi Kawano, Toshihiko Hidaka, Shusaku Nakashima, Tsuyoshi Kasama, Tamio Teramoto & Toshihiro Nanki. (2021) Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study. Rheumatology and Therapy 8:4, pages 1585-1601.
Crossref
Crossref
Esther F. Vicente-Rabaneda, Belén Atienza-Mateo, Ricardo Blanco, Lorenzo Cavagna, Julio Ancochea, Santos Castañeda & Miguel Á. González-Gay. (2021) Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. Autoimmunity Reviews 20:6, pages 102830.
Crossref
Crossref
Kei Watari, Satoru Konnai, Naoya Maekawa, Tomohiro Okagawa, Yasuhiko Suzuki, Shiro Murata & Kazuhiko Ohashi. (2019) Immune inhibitory function of bovine CTLA-4 and the effects of its blockade in IFN-γ production. BMC Veterinary Research 15:1.
Crossref
Crossref
M. A. Borisova & G. V. Lukina. (2019) Analysis of the use of a selective modulator of cosmulation of T‑lymphocytes abatacept in the treatment of rheumatoid arthritis: data from international clinical practice. Medical alphabet 1:18, pages 13-23.
Crossref
Crossref